Black Diamond Therapeutics, Inc. Share Price
NASDAQ: BDTX | Micro CapBlack Diamond Therapeutics, Inc. Stock Performance
Open $1.95 | Prev. Close $1.93 | Circuit Range N/A |
Day Range $1.91 - $1.98 | Year Range $1.60 - $4.94 | Volume 25,967 |
Average Traded $1.93 |
Black Diamond Therapeutics, Inc. Share Price Today
As of 9 August 2026, Black Diamond Therapeutics, Inc.'s share price is $1.92. The stock opened at $1.95, compared to its previous close of $1.93. During today's trading session, Black Diamond Therapeutics, Inc.'s share price traded between $1.91 and $1.98, with an average price of $1.94. Over the past 52 weeks, the stock has recorded a high of $4.94 and a low of $1.60. In terms of performance, Black Diamond Therapeutics, Inc.'s share price has declined by 22.31% over the last six months and is down 30.11% on a year-on-year basis.
Black Diamond Therapeutics, Inc. Share Price Chart
Black Diamond Therapeutics, Inc. Stock Fundamentals & Key Indicators
Market Cap $108.90M | PE Ratio (TTM) 4.91 | Dividend Yield N/A |
EPS (TTM) $0.39 | Revenue (TTM) $70.00M | Return On Equity (TTM) 19.93% |
Profit Margin 31.95% | Debt to Equity 0.14 | Quarterly Earnings Growth YoY N/A |
About Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Black Diamond Therapeutics, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $1.68 | $1.92 | +13.95% |
Jul 2026 | $1.85 | $1.69 | -8.67% |
Jun 2026 | $2.21 | $1.84 | -17.63% |
May 2026 | $2.63 | $2.24 | -15.79% |
Apr 2026 | $2.24 | $2.66 | +24.88% |
Mar 2026 | $2.34 | $2.13 | -13.59% |
Feb 2026 | $2.47 | $2.46 | -0.60% |
Jan 2026 | $2.46 | $2.48 | +1.64% |
Dec 2025 | $3.76 | $2.44 | -36.13% |
Nov 2025 | $3.95 | $3.82 | -1.80% |
Oct 2025 | $3.83 | $3.89 | +2.64% |
Sep 2025 | $2.76 | $3.79 | +38.32% |
BDTX Share Price FAQs
What is Black Diamond Therapeutics, Inc. share price today?
What is the 52 week high and 52 week low of Black Diamond Therapeutics, Inc. stock?
What is BDTX's market capitalisation today?
What is the 5 year returns of BDTX?
What is the high & low stock price of BDTX today?
Can I buy BDTX shares in India?